Ovarian transitional cell carcinoma represents a poorly differentiated form of high-grade serous or endometrioid adenocarcinoma

American Journal of Surgical Pathology

Volumn 37, Issue 7, 2013, Pages 1091-1099

  Takeuchi, Tadahisa ^a   Ohishi, Yoshihiro ^a,b   Imamura, Hiroko ^a   Aman, Murasaki ^a   Shida, Kaai ^a   Kobayashi, Hiroaki ^c   Kato, Kiyoko ^c   Oda, Yoshinao ^a,b  

^a Departments of Anatomical Pathology   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Brenner tumor; Poorly differentiated adenocarcinoma; Transitional cell carcinoma

Indexed keywords

PROTEIN P53; TUMOR MARKER;

ARTICLE; BRENNER TUMOR; CYSTADENOCARCINOMA; ENDOMETRIOID CARCINOMA; FEMALE; GENETICS; HUMAN; METABOLISM; MULTIPLE CANCER; MUTATION; NUCLEOTIDE SEQUENCE; OVARY TUMOR; PATHOLOGY; TRANSITIONAL CELL CARCINOMA;

BRENNER TUMOR; CARCINOMA, ENDOMETRIOID; CARCINOMA, TRANSITIONAL CELL; CYSTADENOCARCINOMA, SEROUS; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MUTATION; NEOPLASMS, MULTIPLE PRIMARY; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84880292132     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3182834d41     Document Type: Article

References (28)

1. Tavassoli FA, Devilee P. World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of the Breast and Female Genital Organs. Lyon: IARC Press; 2003.
2. Cuatrecasas M, Catasus L, Palacios J, et al. Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas. Am J Surg Pathol. 2009;33:556-567.
3. Ali RH, Seidman JD, Luk M, et al. Transitional cell carcinoma of the ovary is related to high-grade serous carcinoma and is distinct from malignant Brenner tumor. Int J Gynecol Pathol. 2012;31: 499-506.
4. McCluggage WG. My approach to and thoughts on the typing of ovarian carcinomas. J Clin Pathol. 2008;61:152-163.
5. Logani S, Oliva E, Amin MB, et al. Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers: histogenetic and diagnostic implications. Am J Surg Pathol. 2003;27:1434-1441.
6. Kurman RJ, Ellenson LH, Ronnett BM. Blaustein's Pathology of the Female Genital Tract. New York: Springer; 2010.
7. Kobel M, Kalloger SE, Baker PM, et al. Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study. Am J Surg Pathol. 2010;34:984-993.
8. Silva EG, Robey-Cafferty SS, Smith TL, et al. Ovarian carcinomas with transitional cell carcinoma pattern. Am J Clin Pathol. 1990;93:457-465.
9. Gershenson DM, Baker VV, Price JE, et al. Molecular profile of advanced-stage transitional cell carcinoma of the ovary. Am J Obstet Gynecol. 1997;177:120-125.
10. Eichhorn JH, Young RH. Transitional cell carcinoma of the ovary: a morphologic study of 100 cases with emphasis on differential diagnosis. Am J Surg Pathol. 2004;28:453-463.
11. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155-168.
12. Yemelyanova A, Vang R, Kshirsagar M, et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol. 2011;24: 1248-1253.
13. Kobel M, Reuss A, Bois A, et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol. 2010;222:191-198.
14. Oda Y, Sakamoto A, Satio T, et al. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma. Mod Pathol. 2000;13:994-1004.
15. Fujita K, Yamamoto H, Matsumoto T, et al. Sessile serrated adenoma with early neoplastic progression: a clinicopathologic and molecular study. Am J Surg Pathol. 2011;35:295-304.
16. Kurihara S, Oda Y, Ohishi Y, et al. Endometrial stromal sarcomas and related high-grade sarcomas: immunohistochemical and molecular genetic study of 31 cases. Am J Surg Pathol. 2008;32:1228-1238.
17. Ohishi Y, Kurihara S, Aman M, et al. "Piling up" clear cells in mullerian-type mucinous and mixed cell-type borderline tumor do not represent concomitant clear cell neoplasms. Hum Pathol. 2012;43:1618-1626.
18. Singer G, Stohr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol. 2005;29:218-224.
19. Kmet LM, Cook LS, Magliocco AM. A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors. Cancer. 2003;97:389-404.
20. Costa MJ, Hansen C, Dickerman A, et al. Clinicopathologic significance of transitional cell carcinoma pattern in nonlocalized ovarian epithelial tumors (stages 2-4). Am J Clin Pathol. 1998;109: 173-180.
21. Robey SS, Silva EG, Gershenson DM, et al. Transitional cell carcinoma in high-grade high-stage ovarian carcinoma. An indicator of favorable response to chemotherapy. Cancer. 1989;65:939-947.
22. Hollingsworth HC, Steinberg SM, Silverberg SG, et al. Advanced stage transitional cell carcinoma of the ovary. Hum Pathol. 1996;27:1267-1272.
23. Campbell IG, Russell SE, Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004;64:7678-7681.
24. Bell DA. Origins and molecular pathology of ovarian cancer. Mod Pathol. 2005;18:S19-S32.
25. Cho KR. Ovarian cancer update: lessons from morphology, molecules, and mice. Arch Pathol Lab Med. 2009;133:1775-1781.
26. Madore J, Ren F, Filali-Mouhim A, et al. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. J Pathol. 2010;220:392-400.
27. Zhang L, Liu Y, Hao S, et al. IMP2 expression distinguishes endometrioid from serous endometrial adenocarcinomas. Am J Surg Pathol. 2011;35:868-872.
28. Karnezis AN, Aysal A, Zaloudek CJ, et al. Transitional cell-like morphology in ovarian endometrioid carcinoma: morphologic, immunohistochemical, and behavioral features distinguishing it from high-grade serous carcinoma. Am J Surg Pathol. 2013;37: 24-37.